For a total of five consecutive years of therapy approved.
Was Aromasin in the United States in 2005 for the treatment of postmenopausal women with estrogen-receptor positive early breast cancer after two to three years of tamoxifen, for a total of five consecutive years of therapy approved. It use in Canada use in Canada, Japan and South America. Currently, Aromasin is available in more than 80 countries and approved in the early breast cancer in more than 40 countries. From Pfizer Inc.e information, including full prescribing information, please visit or 1-888-AROMASIN.
Published. Kaiser Family Foundation. 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.
Earlier results of the IES study, the U.S. FDA and European approvals of Aromasin for treatment of early breast cancer out, found that postmenopausal hormone receptor-positive patients, which represented 85 percent of all patients in the study, the switched Aromasin reduces the risk of breast cancer recurring by 35 percent as compared to patients who remained on tamoxifen for 5 years. Longer survival.Study Fast-track status September 2004 by the FDA Merck obtained the the exclusive worldwide licensing rights from Oncothyreon Inc., Bellevue, Washington, has developed in Europe by Merck KGaA and in the United States by its affiliate, EMD Serono Inc.
Oncothyreon is a biotechnology company specialized in to development of innovative therapeutic items for treating Krebs. Oncothyreon destination be the development and commercialization of novel synthetic vaccines and selective small molecules which improving the potential to the life and the results of cancer patients. Information visit information, please visit Merck Serono is the division for innovative prescription pharmaceuticals of Merck, a global pharmaceutical or chemical company.
More information on the START study or an participating centers and eligibility, walk the study, is also listed on Oncothyreon.